Displaying drugs 3201 - 3225 of 5285 in total
IRX-2
IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.
Investigational
Propamidine
Experimental
Investigational
hu3S193
Investigational
19-norandrostenedione
19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
In the...
Experimental
Illicit
Garetosmab
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Inhibitor Idd 384
Experimental
Tinengotinib
Investigational
Matched Iupac: … (2-chlorophenyl)-6-methyl-13-(morpholin-4-yl)-2,4,5,8,12-pentaazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10 …
Ketobemidone
Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or...
Investigational
Gantenerumab
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
V590
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration …
GTI-2501
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor...
Investigational
Matched Description: … novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I …
ChulaCov19 mRNA vaccine
The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies . The next phase of this study is for...
Investigational
Matched Description: … The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January …
Istaroxime
Investigational
Isuzinaxib
Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).
Investigational
Refametinib
Investigational
Chiniofon
Experimental
5,10-Methylene-6-Hydrofolic Acid
Experimental
CP-601927
CP-601,927 has been used in trials studying the basic science and treatment of Major Depressive Disorder.
Investigational
Matched Iupac: … (1S,8R)-4-(trifluoromethyl)-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene …
IDM-1
IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Investigational
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Displaying drugs 3201 - 3225 of 5285 in total